We are now in crisis again because of Donald Trump’s executive order freezing aid. Surely local drug manufacture now needs to be implemented without any further delay?

TUESDAY, Feb. 12, 2025 (HealthDay News) -- A federal judge has ordered the U.S. Centers for Disease Control and Prevention ...

Gilead stock surged above a buy zone Wednesday after the company obliterated fourth-quarter forecasts and issued an upbeat profit outlook.

Big drug maker Gilead expects to take a billion-dollar hit this year via drug-pricing provisions in the Inflation Reduction ...

With Gilead Sciences' long-acting lenacapavir unlocking a reinvigorated focus on the pre-exposure prophylaxis (PrEP) market ...

Gilead beat consensus estimates in Q4 with $7.6 billion in revenue, driven largely by its HIV drug Biktarvy and CAR T therapies Trodelvy and Yescarta.

Gilead Sciences is rated a Strong Buy due to strong Q4 2024 results and a robust HIV franchise. Check out my 12-month price ...

The chaos and uncertainty surrounding vital AIDS relief programs have needlessly threatened millions of lives, writes Drs.

The pages that are set to be revived include information for patients about HIV testing and HIV prevention medication, ...

Reactions to the changes in USAID run the gamut. Some leading voices — like Mexico's president — are in favor. Others fear ...

Gilead Sciences reported strong fourth-quarter earnings with significant growth in its HIV and oncology segments.

A federal judge on Tuesday ordered government agencies to restore public access to health-related webpages and datasets that ...